Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Bringing precision medicine and MRD into clinical strategies

Lars Bullinger • 15 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Azacitidine Midostaurin

Lars Bullinger, MD, Charité University of Medicine, Berlin, Germany, discusses the value of measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lars Bullinger

1:56
Minimal gene panel in AML
Lars Bullinger • 15 Jun 2020
2:09
EHA: AML immuno-oncology updates
Lars Bullinger • 15 Jun 2020
1:36
Innovations in MDS and AML treatment
Lars Bullinger • 15 Jun 2020
1:51
Novel insights into genomic classification and prognosis in AML
Lars Bullinger • 15 Jun 2020

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals